Loading clinical trials...
Loading clinical trials...
Korean Post Marketing Surveillance for Litfulo Capsule
The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.
To evaluate the safety of Litfulo Capsule after marketing, with regard to the following clauses in routine clinical practice. * Adverse Events (AEs)/ Adverse Drug Reactions (ADRs) * Unexpected Adverse Events (AEs)/ADRs that have not been reflected in the approved drug label * Serious Adverse Events (SAEs)/Serious Adverse Drug Reaction (SADRs) * Adverse Event of Special Interest(AESI) * Serious Infections, defined as any infection (viral, bacterial, and fungal) requiring parenteral antimicrobial therapy or hospitalization for treatment or meeting other criteria that require the infection to be classified as serious adverse event * Opportunistic infections and Herpes Zoster * Malignancy
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Pfizer, Inc
Seoul, South Korea
Start Date
August 27, 2025
Primary Completion Date
March 23, 2030
Completion Date
March 23, 2030
Last Updated
November 20, 2025
3,000
ESTIMATED participants
Litfulo
DRUG
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions